Latest Healthcare News

Ryman Healthcare reported a 13% revenue increase to NZD 413.8 million for H1 2025, yet swung to a significant net loss of NZD 45.2 million and suspended dividends, raising questions about its financial trajectory.

Ryman Healthcare reports a significant financial turnaround with its first positive free cash flow in over ten years, alongside upgraded sales and cost-saving targets for FY26 and completion of a major NZD 2 billion refinancing.

Ryman Healthcare has reported its first positive free cash flow in over a decade, driven by cost reductions and stronger sales momentum, while upgrading its sales guidance for FY26.

Adherium Limited has reached a pivotal commercial milestone by expanding its Remote Patient Monitoring program across 110 U.S. Allergy Partners clinics, activating nearly 70% of the network and onboarding close to 700 patients in six months.

Anatara Lifesciences has completed the final tranche of its placement, issuing over 66 million shares and granting options to its lead manager, marking a key step in its capital raising strategy.

InhaleRX Limited has announced a non-renounceable entitlement offer to raise approximately $247,668 by issuing nearly 10 million new shares at 2.5 cents each, accompanied by free attaching options. The offer opens on 5 December and closes on 17 December 2025.

InhaleRx Limited has introduced SRX-25, an oral fixed-dose combination therapy targeting Treatment-Resistant Depression, aiming to improve patient access and adherence. The company also secured $1 million in capital to advance clinical development and plans a strategic rebrand.

PainChek Ltd has secured FDA De Novo clearance for its Adult App, marking a pivotal entry into the US long-term care market and setting the stage for global expansion including its Infant App.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Recce Pharmaceuticals has reported compelling preclinical results for its inhaled anti-infective RECCE 327, demonstrating potent activity against multidrug-resistant pneumonia bacteria in mice models.

Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.

Enlitic has expanded its collaboration with GE Healthcare, adding around US$1 million in revenue and broadening the use of its medical imaging data solutions. This move underscores growing trust and integration between the two companies.